Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis.
Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. J Am Acad Dermatol. 2010 Sep; 63(3):448-56.
View in:
PubMed
subject areas
Adalimumab
Adolescent
Adult
Aged
Analysis of Variance
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Canada
Dose-Response Relationship, Drug
Double-Blind Method
Drug Administration Schedule
Drug-Related Side Effects and Adverse Reactions
Female
Follow-Up Studies
Humans
Male
Maximum Tolerated Dose
Middle Aged
Multivariate Analysis
Psoriasis
Severity of Illness Index
Treatment Outcome
United States
authors with profiles
Kenneth Gordon